Arrotex Pharmaceuticals is taking steps to ensure the Australian market has greater supply of its dipyridamole and aspirin combination product Diasp SR following the discontinuation of Asasantin SR.
Diasp SR has been ‘a’ flagged by the Pharmaceutical Benefits Scheme (PBS) as bioequivalent and interchangeable with Asasantin SR.
Arrotex is working with its global supply chain to ensure Diasp SR will be available to the Australian market.
Supply of Diasp SR will build over time and it is anticipated stock will become available in Australia in the coming weeks.
The dipyridamole and aspirin combination is used to prevent the recurrence of ischaemic stroke or transient cerebral ischaemic events.
As the largest supplier to the PBS by volume, Arrotex is committed to ensuring Australian patients have ongoing access to their medicines.
Arrotex wishes to reassure pharmacists that their patients will continue to have access to a PBS subsidised dipyridamole and aspirin combination.
For enquiries pertaining to Diasp SR supply, please phone: 1800 276 839.
